Evidence map›Paper›PMID 42512378›Full record

ReviewCancers2026

Pancreatic Acinar Cell Carcinoma: A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities.

Noor Farhoud, Raed Moh'd Taiseer Al-Rajabi, Joaquina Celebre Baranda, Haoran Li, Wei Zhang, Ravi Kumar Paluri, Ashish Manne, Prasad Dandawate, Weijing Sun, Anup Kasi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Noor FarhoudDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Raed Moh'd Taiseer Al-RajabiDepartment of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA.
Joaquina Celebre BarandaDepartment of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0002-0917-6307
Haoran LiDepartment of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA.
Wei ZhangDepartment of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0003-3154-0256
Ravi Kumar PaluriDepartment of Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.ORCID 0000-0002-2317-7082
Ashish ManneDepartment of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.ORCID 0000-0003-2356-5162
Prasad DandawateDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.ORCID 0000-0002-1141-3703
Weijing SunDepartment of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA.ORCID 0000-0001-6549-9605
Anup KasiDepartment of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic acinar cell carcinoma (PACC) is a rare exocrine pancreatic malignancy accounting for approximately 1-2% of adult pancreatic neoplasms. Although historically grouped with pancreatic ductal adenocarcinoma (PDAC), accumulating evidence demonstrates that PACC represents a biologically distinct entity with unique clinical, pathologic, and molecular characteristics. Compared with PDAC, PACC more commonly presents as a large pancreatic mass, is less frequently associated with obstructive jaundice, and exhibits lower rates of

Indexed as

acinar cell carcinomaBRAF fusiongene fusionshomologous recombination deficiencyimmunotherapymolecular profilingpancreatic acinar cell carcinomapancreatic cancerpancreatic neoplasmsprecision oncologytargeted therapy

Identifiers

PMID42512378
PMCPMC13406766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.